IGM Biosciences Inc (IGMS) Stock
IGMS is no longer traded. IGM Biosciences was delisted from the Nasdaq in August 2025.
Prices on this page are historical; the last trade was August 12, 2025 at $1.30.
IGM Biosciences stock price history
IGMS final trading statistics
- Final close
- $1.30
- Final trading day
- Aug 12, 2025
- Market cap at delisting
- $47.57M
- Shares outstanding
- 36.59M
- Final 52-week range
- $0.92 – $22.50
- Avg. volume (final 3 mo.)
- 614,088
- All-time high (split-adj.)
- $121.23 · Feb 2021
- All-time low (split-adj.)
- $1.02 · Apr 2025
- Return since IPO
- -94.7%
- Beta
- 0.59
- Book value / share
- $1.68
- Price / book
- 0.78
IGM Biosciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $2.68M | -$195.8M | -$3.24 |
| FY2023 | $2.13M | -$246.4M | -$4.81 |
| FY2022 | $1.07M | -$214.2M | -$5.37 |
| FY2021 | $366.0K | -$160.7M | -$4.93 |
| FY2020 | $0.00 | -$80.3M | -$2.65 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
IGM Biosciences stock FAQ
What happened to IGM Biosciences stock?
IGM Biosciences stock was delisted from the Nasdaq. Its final close was $1.30 on August 12, 2025.
Is IGMS stock still trading?
No. IGMS was delisted from the Nasdaq in August 2025 and no longer trades on a U.S. exchange.
What was the last price of IGMS stock?
IGMS closed at $1.30 on its final trading day, August 12, 2025, for a market value of about $47.57M.
What were IGM Biosciences's revenue and earnings in its last full fiscal year?
IGM Biosciences reported revenue of $2.68M and net income of -$195.8M in fiscal 2024, its last full year as a public company.
When did IGM Biosciences go public?
IGM Biosciences Inc stock began trading on September 18, 2019.